Latest Conference Articles

Afatinib markedly prolonged PFS compared with standard chemotherapy in patients with advanced lung adenocarcinomas that tested positive for EGFR mutations, particularly one of two common mutation types.

Bevacizumab plus chemotherapy as a second-line treatment for metastatic colorectal cancer improved survival among patients whose disease had progressed after first-line combination therapy with bevacizumab.

Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial

Dr. Mathias Rummel, from University Hospital Giessen in Germany, on Bendamustine Plus Rituximab in Indolent and Mantle Cell Lymphomas

T-DM1 extended progression-free survival by 3.2 months in women with HER2-positive locally advanced or metastatic breast cancer.

Bendamustine should become the preferred chemotherapy standard of care in initial combination regimens for indolent lymphomas and mantle cell lymphoma.

Patients with metastatic, hormone-sensitive prostate cancer and minimal disease spread experience a two-year boost in median survival when treated with continuous, rather than intermittent, hormonal therapy.

Dr. Eric Pujade-Lauraine, from Université de Paris Descartes, France, on the AURELIA Bevacizumab Trial for Platinum-Resistant Ovarian Cancer.

Dr. Suzanne Topalian, from Johns Hopkins University School of Medicine, on the PD-1 Targeted Therapy BMS-936558

Combining bevacizumab with standard chemotherapy reduced the risk of disease progression by 52% in patients with platinum-resistant ovarian cancer.

Study finds that more than two-thirds of patients with metastatic kidney cancer prefer pazopanib over another FDA-approved treatment, sunitinib.

Adolescent and young adult patients between the ages of 16 and 30 had poorer outcomes when given the same treatment regimen as younger acute lymphoblastic leukemia patients.

An immunotherapy agent that targets the PD-1 pathway demonstrated response rates as high as 28% in an early-phase study involving patients with different tumor types.

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on Dabrafenib and Trametinib Combination Side Effects

Pharmaceutical industry analysts and companies have been weighing in on their selections for the most noteworthy research to be presented during the 2012 ASCO Annual Meeting.

American Society of Clinical Oncology (ASCO) 2012 Annual Meeting video highlights, from OncLive TV.

On May 16, the ASCO highlighted the results of five ground-breaking studies in advance of its annual meeting held in Chicago from June 1-5, 2012.

Dr. Andre Goy, from John Theurer Cancer Center, Highlights Research From the 2012 ASCO Meeting.

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on the Unique Attributes of Neoadjuvant Zytiga.

Dr. Paul W. Ladenson, from Johns Hopkins Medicine, on Diagnosis of Thyroid Nodules

Results of a multi-generational case study strengthen the case for genetic screening in cases of hereditary thyroid cancer.

Patients are more likely to present with regional or distant metastases and experience lower rates of cancer-free survival depending on where they live.

Researchers find that overexpression of a specific gene is associated with poor survival in patients with adrenocortical carcinoma.

Another presentation at the AACE meeting on Thursday featured Dr. Saleh Aldasouqi, FACE, ECNU, discussing a topic that is not heard about too often in the medical world: tattoos.

Patients who live far from medical facilities benefit from having "virtual" conversations with their doctors and are comfortable with that arrangement.

Photos taken from the AACE 21st Annual Scientific and Clinical Congress held at the Pennsylvania Convention Center, from May 23-27, 2012.

A look at two poster presentations from the AACE meeting focusing on insular carcinoma and medullary thyroid cancer.

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on the Dabrafenib Plus Trametinib Combination for Melanoma

Combined neoadjuvant treatment with abiraterone acetate (Zytiga) plus standard hormonal therapy before prostatectomy eradicated or nearly eradicated tumors in 34% of patients with localized high-risk prostate cancer.

A combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib has shown promising activity in patients with advanced melanoma.